Ranbaxy Laboratories

Malvinder Singh asked to deposit 3.5 mn Singapore dollars, 'disobeyed orders' says Delhi HC

The court’s order came after it was informed by the counsel for Malvinder, who was present in the court, that his 45 lakh equity shares in Religare Healthcare Pvt Ltd were sold in Singapore in April.

Fortis Healthcare: Shivinder Singh sues brother Malvinder alleging oppression, mismanagement of business; moves NCLT

Last month, the brothers who are co-promoters of the Group had put the blame on former Religare Enterprises Chairman and Managing Director Sunil Godhwani for the group's troubles.

Fortis Healthcare board approves demerger, to sell hospital business to Manipal, TPG Capital

Manipal Hospitals, part of Manipal Education and Medical Group (MEMG), is owned by Dr Ranjan Pai and has been backed by TPG, a leading global alternative asset firm and experienced healthcare investor since 2015.

Fortis vs Daiichi Sankyo: Singh brothers resign after Delhi HC upholds Rs 3,500 cr arbitral award to Japanese pharma

A tribunal in Singapore had passed the verdict in favour of Daiichi holding that the former Ranbaxy promoters had concealed certain information

Sun Pharma Q1 net profit down by 60% over integration woes

Total income of the company increased however to Rs 6,767.58 crore during the first quarter of 2015-16 as against Rs 6,341.21 crore for the year ago period.

Sun Pharma reports Q4 net profit at Rs 888 cr, Ranbaxy deal shrinks earnings

Net sales of the company stood at Rs 27,286.50 crore for the year ended March 31. The same stood at Rs 16,004.39 crore in the last year.

Daiichi Sankyo's misery ends, block deal to give company coup de grâce

Even after allowing for control premium, the price that Daiichi Sankyo paid for Ranbaxy Laboratories was clearly excessive, and those in the know said sagely that winner’s curse would have its say sooner than later.

FDA ban: Ranbaxy to take 'appropriate action' for lapses at Toansa

Ranbaxy Laboaratories today said it will take 'appropriate management action' for the lapses at the manufacturing facility after the conclusion of an internal investigation.<br /><br />

10 things you need to know before the opening bell

Asian shares paused on Friday as investors sat back to ponder the US Federal Reserve's policy outlook, a day after the world's most powerful central bank triggered a global rally in riskier asset markets with an unexpected decision to maintain its stimulus.

FDA ban: Why Ranbaxy shares have tanked 35% when Sensex is soaring

Ranbaxy Laboratories tanked 35% to Rs 297 in opening trade after CNBC-TV18 reported that the US Food and Drug Administration (USFDA) has issued import alert on the company's Mohali unit.